125 related articles for article (PubMed ID: 8698449)
1. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
Bernink PJ; Prager G; Schelling A; Kobrin I
Hypertension; 1996 Mar; 27(3 Pt 1):426-32. PubMed ID: 8698449
[TBL] [Abstract][Full Text] [Related]
2. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
[TBL] [Abstract][Full Text] [Related]
3. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.
Bursztyn M; Kadr H; Tilvis R; Martina B; Oigman W; Talberg J; Kobrin I
Am Heart J; 1997 Aug; 134(2 Pt 1):238-47. PubMed ID: 9313603
[TBL] [Abstract][Full Text] [Related]
4. The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect.
Carney S; Wing L; Ribeiro A; Kallwellis R; Zimlichman R; Viskoper RJ; Mion D; Kobrin I
J Hum Hypertens; 1997 Jul; 11(7):459-66. PubMed ID: 9283064
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
Oparil S; Bernink P; Bursztyn M; Carney S; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):12C-19C. PubMed ID: 9286849
[TBL] [Abstract][Full Text] [Related]
6. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
Braun S; van der Wall EE; Emanuelsson H; Kobrin I
J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
[TBL] [Abstract][Full Text] [Related]
7. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
Bakx AL; van der Wall EE; Braun S; Emanuelsson H; Bruschke AV; Kobrin I
Am Heart J; 1995 Oct; 130(4):748-57. PubMed ID: 7572582
[TBL] [Abstract][Full Text] [Related]
8. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
[TBL] [Abstract][Full Text] [Related]
9. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
Kobrin I; Charlon V; Lindberg E; Pordy R
Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group.
Karch FE; Pordy R; Benz JR; Carr A; Lunde NM; Marbury T; Tarro JN
Clin Ther; 1997; 19(6):1368-78. PubMed ID: 9444446
[TBL] [Abstract][Full Text] [Related]
11. Differential properties of mibefradil in hypertension and angina.
Kobrin I
J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
[TBL] [Abstract][Full Text] [Related]
12. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Dalle Ave S; Ward C; Lindberg E
Am J Hypertens; 1997 Feb; 10(2):189-96. PubMed ID: 9037327
[TBL] [Abstract][Full Text] [Related]
13. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
Frishman WH; Bittar N; Glasser S; Habib G; Smith W; Pordy R
Clin Cardiol; 1998 Jul; 21(7):483-90. PubMed ID: 9669057
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.
Massie BM; Chrysant SG; Jain A; Weir M; Weiss R; Korrin I
Clin Cardiol; 1997 Jun; 20(6):562-8. PubMed ID: 9181268
[TBL] [Abstract][Full Text] [Related]
16. Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD. Mibefradil Hypertension Study Group.
Bittar N
Clin Ther; 1997; 19(5):954-62. PubMed ID: 9385483
[TBL] [Abstract][Full Text] [Related]
17. Cytosolic calcium and lymphoproliferative response during calcium antagonism in men.
Lijnen P; Fagard R; Petrov V
Eur J Clin Pharmacol; 1999 Feb; 54(12):911-5. PubMed ID: 10192750
[TBL] [Abstract][Full Text] [Related]
18. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
[TBL] [Abstract][Full Text] [Related]
19. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
Schneeweiss A; Kobrin I; Charlon V; Caspi A; Marmor A; Sclarovsky S; Reisin L; Schlesinger Z
Am Heart J; 1998 Feb; 135(2 Pt 1):272-80. PubMed ID: 9489976
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension.
Schmitt R; Kleinbloesem CH; Belz GG; Schroeter V; Feifel U; Pozenel H; Kirch W; Halabi A; Woittiez AJ; Welker HA
Clin Pharmacol Ther; 1992 Sep; 52(3):314-23. PubMed ID: 1526090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
